News | Prostate Cancer | October 16, 2019

GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent

Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment

GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent

October 16, 2019 — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and, as and when approval is received, all subsequent commercial and distribution activities.

Today, prostate cancer is the fourth largest cancer type, accounting for just over 1.2 million new cases and over 350,000 fatalities around the globe in 2018. The diagnostic workflow for detecting prostate cancer starts through a blood test or biopsy, after which patients are typically referred for PET/CT imaging so that radiologists can see their tumor, lymph nodes and any metastasis in order to decide the appropriate course of treatment. The ‘heatmap’ style image enabled by the new tracer shows the precise location and intensity of PSMA, which is expressed on the surface of prostate cancer cells.

Theragnostics has reported data from a phase two clinical study which met its primary and secondary endpoints, demonstrating that one third of newly diagnosed prostate cancer patients — and more than 50 percent of patients with biochemically recurrent disease — had their treatment plans modified as a result of a GalliProst scan. The change in patient management increased to 75 percent in a post-radical radiotherapy setting.

This marks the second agreement between Theragnostics and GE Healthcare, following an agreement in 2018 for a diagnostic tracer for imaging kidney function and scarring. 

For more information: www.gehealthcare.com, www.theragnostics.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
RSNA's open data repository will compile images and correlative data to create a comprehensive source for COVID-19 research and education efforts #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 30, 2020
March 30, 2020 — The medical imaging community around the world is uniting to help address the...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Typical CT imaging features for COVID-19. Unenhanced, thin-section axial images of the lungs in a 52-year-old man with a positive RT-PCR (A-D) show bilateral, multifocal rounded (asterisks) and peripheral GGO (arrows) with superimposed interlobular septal thickening and visible intralobular lines (“crazy-paving”). Routine screening CT for diagnosis or exclusion of COVID-19 is currently not recommended by most professional organizations or the US Centers for Disease Control and Prevention. Image courtesy of RSNA

News | Coronavirus (COVID-19) | March 26, 2020
March 26, 2020 — The Radiological Society of North America (RSNA
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Representative examples of the attention heatmaps generated using Grad-CAM method for (a) COVID-19, (b) CAP, and (c) Non-Pneumonia. The heatmaps are standard Jet colormap and overlapped on the original image, the red color highlights the activation region associated with the predicted class. COVID-19 = coronavirus disease 2019, CAP = community acquired pneumonia. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | March 20, 2020
March 20, 2020 — An arti...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Series CT scans in 35-year-old woman with COVID-19 pneumonia. (a) Scan obtained on illness days 1 showed multiple pure ground-glass opacity (GGO) mainly in right lower lobe. (b) Scan obtained on illness days 5 showed increased extent of GGO and early consolidation. (c) Scan obtained on illness days 11 showed multiple consolidation with almost the same extent. (d) Scan obtained on illness days 15 showed a mixed pattern with a slightly smaller extent, and the perilobular consolidation might suggest the presence of organizing pneumonia. The patient was discharged on illness days 17. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | March 20, 2020
March 20, 2020 — In a new study pub